Skip to main content
padlock icon - secure page this page is secure

Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment

Buy Article:

$59.00 + tax (Refund Policy)

Heider U, Kaiser M, Müller C, Jakob C, Zavrski I, Schulz C-O, Fleissner C, Hecht M, Sezer O. Bortezomib increases osteoblast activity in myeloma patients irrespective of response to treatment. Abstract: 

Objectives: Myeloma bone disease is a result of excessive osteoclast activation and impaired osteoblast function. Recent in vitro studies suggested that proteasome inhibitors might increase osteoblast function. Methods: We analyzed serum markers of osteoblast activity in 25 patients with multiple myeloma receiving bortezomib alone or in combination with dexamethasone. As control, serum samples from 58 consecutive myeloma patients receiving a therapy different than bortezomib (i.e. adriamycin/dexamethasone, melphalan/prednisone or thalidomide) were evaluated. The serum concentrations of bone-specific alkaline phosphatase (BAP) and osteocalcin were quantified before initiation of treatment and after 3 months. Results: In patients treated with bortezomib, mean serum levels of osteocalcin significantly increased from 6.3 to 10.8 g/L (P = 0.024), while mean BAP levels increased from 19.7 to 30.2 U/L (P < 0.0005). Of interest, the increase in BAP was significant both in responders and non-responders. In contrast, the control group did not show a statistically significant change in BAP (24.8 U/L vs. 23.3 U/L) and osteocalcin (6.8 g/L vs. 6.5 g/L) before and after the treatment. Conclusion: These data show that treatment with bortezomib leads to enhanced markers of osteoblast activity in patients with myeloma. The comparison with the control group suggests that the effect on osteoblasts is unique to the proteasome inhibitor.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: bone; bortezomib; myeloma; osteoblast; proteasome

Document Type: Research Article

Affiliations: 1: Department of Hematology and Oncology, University Hospital Charité, Berlin, Germany 2: Institute for Laboratory Medicine, University Hospital Charité, Berlin, Germany

Publication date: September 1, 2006

  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more